# Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

> **NCT02998775** · EARLY_PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 54 (actual)

## Conditions studied

- Hepatic Impairment; Renal Impairment

## Interventions

- **DRUG:** Plasma Sampling

## Key facts

- **NCT ID:** NCT02998775
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-02
- **Primary completion:** 2017-07-08
- **Final completion:** 2017-07-08
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998775, "Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02998775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*